Oct. 24 at 11:19 AM
$GLUE $10.65
Holding long position at
$7.68 (10.3.25)
https://stocktwits.com/G101SPM/message/630970857
CHANGE EXIT TO
$16.00 from
$10.00.
UPDATE: patient donor-derived peripheral blood mononuclear cells (PBMCs).
In vitro data demonstrated that MRT-6160 decreased TfH cell-mediated B cell activation, differentiation, and immunoglobulin secretion.
In the spontaneous autoimmune disease MRL-Faslpr mouse model, oral administration of MRT-6160 resulted in attenuated proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, organomegaly, and kidney glomerular and interstitial nephritis. MRT-6160 was equivalent or superior to prednisone or anti-CD40L monoclonal antibody treatments across multiple metrics of disease pathology.
